Germline genetic testing, no longer an “exceptional” test offered only to select families with multiple generations of cancer, has become the standard of care for many cancers, including prostate cancer. It is imperative that patients be offered timely testing, as positive results may inform shared patient–physician decision-making for regulatory-approved therapies.
Key Points:
- Indications for and implications of germline testing in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management.
- Germline testing for prostate cancer is vastly underused despite many patients qualifying for testing.
- It is imperative that a variety of well-studied genetics service delivery models be used to help overcome recognized barriers to the implementation of germline testing for prostate cancer so that patients and their families receive the most effective care.
Lynch Syndrome Ireland 